ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 2319

Changes in the Causes and Predictors of Lupus Mortality in Spain Through the Last Decades: Data from the RELESSER Registry
Abstract Number: 2320

Predicting Remission and Low Disease Activity Attainment in Patients with Systemic Lupus Erythematosus
Abstract Number: 2321

Does the Perspective of SLE Patients Match the Expert Opinion and Definitions of Remission and Low Disease Activity State? Prospective Analysis of 500 Patients from a Spanish Multicenter Cohort
Abstract Number: 2322

Identifying SLE Patients with Depression Using a Zero-Inflated Hidden Markov Model and Predicting Factors Associated with Transition from a Non-depressed State to a Depressed State
Abstract Number: 2323

An Electronic Health Record-Based Algorithm for Predicting Systemic Lupus Erythematosus Flares: Integrating Clinical Factors and Social Determinants of Health
Abstract Number: 2324

Leveraging ChatGPT for Real-World Systematic Lupus Erythematosus Data Curation from Electronic Health Records: A Feasibility Study
Abstract Number: 2325

Longitudinal ANA Titers in SLE and ANA-associated Rheumatic Diseases
Abstract Number: 2326

Efficacy and Safety of Voclosporin in Patients with Proteinuria > 2 G/g
Abstract Number: 2327

Hydroxychloroquine Improves Low Complement Levels
Abstract Number: 2328

Deucravacitinib, an Oral, Allosteric, Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Patient-Reported Outcomes in a Phase 2 Trial
Abstract Number: 2329

AMTX-100, a Nuclear Transport Inhibitor, Attenuates Inflammatory Cytokine Production in vitro and Following UV Mediated Skin Inflammation in a Mouse Model of Cutaneous Lupus Erythematosus in vivo
Abstract Number: 2330

Disease-Related Outcomes of Cognitive Behavioral Therapy in Randomized Control Trial for Youth with Childhood-onset SLE: A Secondary Analysis
Abstract Number: 2331

Molecular Predictors of Treatment Response in Two Trials of Abatacept in Systemic Lupus Erythematosus
Abstract Number: 2332

Dapirolizumab Pegol Efficacy by Subgroups in Patients with SLE: A Post Hoc Analysis of Phase 2b Clinical Trial Data
Abstract Number: 2333

Dapirolizumab Pegol Impacts Important Immunologic Pathways in SLE: Pharmacodynamic Analysis of B Cell and Type I Interferon Pathways from a Phase 2b Trial

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].